<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Osteopontin (OPN) is a proinflammatory cytokine implicated in the chemoattraction of monocytes and the development of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Peroxisome proliferator-activated receptor (PPAR)alpha, a ligand-activated transcription factor with pleiotropic anti-inflammatory effects in macrophages, is the molecular target for fibrates, which are frequently used to treat <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> at high risk for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we examined the regulation of OPN by PPARalpha <z:chebi fb="4" ids="48705">agonists</z:chebi> in macrophages and determined the effect of fibrate treatment on OPN plasma levels in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment of human macrophages with the PPARalpha ligands <z:chebi fb="0" ids="47612">bezafibrate</z:chebi> or WY14643 inhibited OPN expression </plain></SENT>
<SENT sid="4" pm="."><plain>PPARalpha ligands suppressed OPN promoter activity, and an activator protein (AP)-1 consensus site conferred this repression </plain></SENT>
<SENT sid="5" pm="."><plain>Overexpression of c-Fos and c-Jun reversed the inhibitory effect of PPARalpha ligands on OPN transcription, and, in chromatin immunoprecipitation assays, PPARalpha ligands inhibited c-Fos and phospho-c-Jun binding to the OPN promoter </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, c-Fos and phospho-c-Jun protein expression was inhibited by PPARalpha <z:chebi fb="4" ids="48705">agonists</z:chebi>, indicating that PPARalpha ligands suppress OPN expression through negative cross talk with AP-1-dependent transactivation of the OPN promoter </plain></SENT>
<SENT sid="7" pm="."><plain>This inhibitory effect of PPARalpha ligands on OPN expression was absent in PPARalpha-deficient macrophages, suggesting a receptor-mediated mechanism of OPN suppression </plain></SENT>
<SENT sid="8" pm="."><plain>Finally, treatment of type 2 diabetic patients with <z:chebi fb="0" ids="47612">bezafibrate</z:chebi> significantly decreased OPN plasma levels </plain></SENT>
<SENT sid="9" pm="."><plain>These results demonstrate a novel mechanism whereby PPARalpha ligands may impact macrophage <z:mp ids='MP_0001845'>inflammatory responses</z:mp> and decrease early proinflammatory markers for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
</text></document>